Arcturus Therapeutics Holdings Inc.
ARCT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $17 | $25 | $29 | $21 |
| % Growth | -30% | -16.6% | 39.9% | – |
| Cost of Goods Sold | $3 | $0 | $0 | $0 |
| Gross Profit | $14 | $25 | $29 | $21 |
| % Margin | 80.5% | 100% | 100% | 100% |
| R&D Expenses | $23 | $30 | $35 | $44 |
| G&A Expenses | $10 | $10 | $11 | $12 |
| SG&A Expenses | $10 | $10 | $11 | $12 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$3 | -$4 | $0 | -$2 |
| Operating Expenses | $30 | $36 | $46 | $54 |
| Operating Income | -$17 | -$12 | -$17 | -$33 |
| % Margin | -96.3% | -47.4% | -57.3% | -159% |
| Other Income/Exp. Net | $3 | $2 | $3 | $3 |
| Pre-Tax Income | -$13 | -$9 | -$14 | -$30 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$13 | -$9 | -$14 | -$30 |
| % Margin | -78.4% | -37.5% | -47.9% | -142.9% |
| EPS | -0.49 | -0.34 | -0.52 | -1.11 |
| % Growth | -44.1% | 34.6% | 53.2% | – |
| EPS Diluted | -0.49 | -0.34 | -0.52 | -1.11 |
| Weighted Avg Shares Out | 27 | 27 | 27 | 27 |
| Weighted Avg Shares Out Dil | 27 | 27 | 27 | 27 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $3 | $3 | $3 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$13 | -$11 | -$16 | -$29 |
| % Margin | -74% | -44.2% | -54.5% | -139% |